Septerna
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
250 E Grand Ave, South San Francisco, Ca...Phone Number
(650) 338-3533Website
www.septerna.comRevenue
$98.9 MillionStock Symbol
SEPNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Septerna
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology company focused on developing new therapies targeting GPCRs. Using its proprietary Native Complex Platform, the company is advancing a pipeline of oral small-molecule drug candidates in areas such as endocrinology, immunology, inflammation, and metabolic diseases, both independently and with partners.Explore more
Septerna Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Septerna your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Septerna is spiking on competitors!
Click to see if Septerna had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Septerna has new funding data
Product Launch: Get notified when Septerna launches new products
Check if Septerna has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Septerna recently announced quarterly report
Septerna, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Septerna
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Septerna
Compare insights from companies similar to Septerna, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Septerna is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Septerna is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Septerna.
Septerna financials insights
Gather financial insights about Septerna, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$100M
2023
Series B
$150M
2024
Stock Offering
$288M
Septerna Tech Stack
A closer look at the technologies used by Septerna
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Person-Based
Earnings, Pharmaceuticals, Business Finance, Finance
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Septerna News & Media
Septerna (SEPN) Names A New CMO, Is The Upside Already Priced In? - Simply Wall St
Septerna (SEPN) has drawn fresh investor attention after appointing Rajiv Patni, M.D., as Chief Medical Officer. The move raises new questions about how his track record in drug development could influence the company’s clinical priorities and risk profile. Septerna’s latest executive change comes after a strong run in the stock, with the share price at US$38.91 and a year to date share price return of 39.06%, alongside a very large 1 year total shareholder return ofSepterna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Septerna, a clinical-stage biotech focused on GPCR-targeted therapies, reported significant insider selling in its latest SEC filing.Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Septerna
Sign Up For FreeTo access detailed company insights
Based in South San Francisco, CA, Septerna is a clinical-stage biotechnology company focused on developing new therapies targeting GPCRs. Using its proprietary Native Complex Platform, the company is advancing a pipeline of oral small-molecule drug candidates in areas such as endocrinology, immunology, inflammation, and metabolic diseases, both ind... Read More
